BAISHIDENG PUBLISHING GROUP INC
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242 Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

Name of Journal: *World Journal of Transplantation*

ESPS Manuscript NO: 29304

Manuscript Type: Original Article

The response to reviewer one's comments:

Currently, all patients receive alemtuzumab induction unless they have a relative contraindication, which include a past history of malignancy, hepatitis or previous significant immunosuppressive burden, when patients receive an anti-CD25 antibody. Historically, patients enrolled into a clinical trial may also have received an anti-CD25 antibody at induction.

Patients receive 500mg of methylprednisolone at induction, followed by 30mg twice a day of prednisolone for 3 days, then 30mg once daily for 4 days.

This information has been added to the manuscript.

Correspondence to: Michelle Willicombe, MA, MRCP, MD, Imperial College Kidney and Transplant Centre, Hammersmith Hospital, South Wharf Road, London W12 0HS, United Kingdom. michelle.willicombe@imperial.nhs.uk

Name: Michelle Willicombe

Signature: MPWillicombe **Date:** 22/9/16